Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Anderson on Recent Advances in Multiple Myeloma Drugs

January 22nd 2014

Pomalidomide (Pomalyst) rode impressive trial results to accelerated FDA approval this year, and Kenneth Anderson thinks it will prove a valuable new tool in the fight against multiple myeloma

Dr. Kumar on the Design of a Phase II Trial of MLN9708

January 15th 2014

Shaji K. Kumar, MD, professor of medicine, Mayo Clinic, describes the design of a phase II trial looking at the single-agent activity of the proteasome inhibitor MLN9708 for the treatment of patients with multiple myeloma.

B-Cell Malignancies: Transforming Expectations and Outcomes

January 6th 2014

With the arrival and incorporation into clinical practice of immunomodulatory drugs (IMiDs) and proteasome inhibitor therapy, patients with multiple myeloma are achieving deep, durable responses and disease control, and are living longer.

Stemline Therapeutics Targets Capacity of Tumors to Adapt and Proliferate

December 17th 2013

The investigational cancer medications being developed by Stemline Therapeutics attack only a tiny percentage of all tumor cells. But those few cells-the stem cells that resist most treatment and drive tumor growth-may just be the most important ones.

Dr. Landgren on Combinations in Newly Diagnosed Myeloma

December 16th 2013

C. Ola Landgren, MD, PhD, from the National Cancer Institute, discusses a phase II trial that explored the combination of carfilzomib, lenalidomide, and dexamethasone followed by maintenance lenalidomide in patients with newly diagnosed multiple myeloma.

Dr. Durie on a More Sensitive Automated Flow Cytometry MRD Test

December 16th 2013

Brian G.M. Durie, MD, chairman, International Myeloma Foundation, hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses a more sensitive automated flow cytometry minimal residual disease (MRD) test.

Dr. Mateos on Elderly Patients With Newly Diagnosed MM

December 16th 2013

MarÃa-Victoria Mateos, MD, PhD, associate professor, hematology, University Hospital of Salamanca, Salamanca, Spain, discusses the design and results of a phase II trial that she presented at the 2013 American Society of Hematology (ASH) Meeting.

Dr. Berenson on a Study of Pomalidomide in R/R Myeloma

December 13th 2013

James R. Berenson, MD, discusses a phase I/II study looking at pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. The study was presented at the 2013 ASH Meeting.

Dr. Shah on Novel Therapies for Multiple Myeloma

December 11th 2013

Jatin J. Shah, MD, from the University of Texas, MD Anderson Cancer Center, describes his excitement over novel therapeutics in development for patients with multiple myeloma.

New Drug Class Shows Activity in Refractory Multiple Myeloma

December 10th 2013

The first-in-class targeted agent filanesib has demonstrated promising activity in patients with relapsed and refractory multiple myeloma.

Dr. Laubach on the Efficacy of Daratumumab in Myeloma

December 10th 2013

Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.

Continuous Lenalidomide Deemed a Standard of Care For Newly Diagnosed Multiple Myeloma

December 9th 2013

The combination of continuous lenalidomide and low-dose dexamethasone extends PFS and trends toward improving OS compared with the standard MPT in patients with transplant-ineligible newly diagnosed multiple myeloma.

Treating Precursor Disease May Stall Multiple Myeloma Progression

December 8th 2013

Intervention in early or "smoldering" myeloma with a three-drug regimen led to complete responses in a group of high-risk patients, suggesting a window of opportunity that may delay or prevent progression to a debilitating disease state.

Longer Bortezomib Duration Linked to Improved Survival in Multiple Myeloma

December 8th 2013

A higher cumulative dose of bortezomib, including a longer duration of treatment and/or higher dose intensity, appears to improve OS in patients with previously untreated multiple myeloma.

New Approaches Explored in Relapsed/Refractory Multiple Myeloma

October 31st 2013

Several protocols of novel immune and targeted agents show promise alone and in combination, including monoclonal antibodies, immune therapies, and newer proteasome inhibitors.

Novel Proteasome Inhibitors for Multiple Myeloma

October 17th 2013

Multiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.

No Age Limit for Bone Marrow Transplantation

October 10th 2013

Age is no longer a consideration when determining whether an older patient with blood cancer is a candidate for stem cell transplantation.

Doxil Availability Once Again in Question

October 9th 2013

Access to Doxil has been inconsistent since mid-2011, when the drug's sole manufacturer announced a voluntary shutdown of production to address significant manufacturing and quality concerns.

Studies Highlight Newly Approved and Novel Multiple Myeloma Treatments

July 26th 2013

Researchers highlighted the latest developments in the treatment of multiple myeloma at the 2013 ASCO Annual Meeting. Noteworthy abstracts included updated data on pomalidomide, as well as research involving the novel agents daratumumab and elotuzumab.

Project Aims to "Bridge the Gap" From Remission to Cure in Multiple Myeloma

June 21st 2013

In an interview with OncologyLive, Brian G.M. Durie, MD, provided details about the Black Swan initiative and how he expects the project to develop.